Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Decitabine + Tetrahydrouridine?
Decitabine + Tetrahydrouridine is a small molecule commercialized by Novo Nordisk, with a leading Phase II program in Sickle Cell...
Data Insights
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Decitabine + Tetrahydrouridine?
Decitabine + Tetrahydrouridine is a small molecule commercialized by Novo Nordisk, with a leading Phase II program in Sickle Cell...